Cerenome, Inc. (CNSY) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Cerenome, Inc. (CNSY) closed at USD 1.69 on 2026-10-14, a change of -88.3 % over the past year, with a market capitalization of USD 14.27M.
Cerenome, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.69 |
| 2026-10-13 | 1.74 |
| 2026-10-12 | 1.81 |
| 2026-10-09 | 1.93 |
| 2026-10-08 | 1.79 |
| 2026-10-07 | 1.64 |
| 2026-10-06 | 1.59 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Cerenome, Inc. key figures
- Previous close
- USD 1.69 (2026-10-14)
- 1-year change
- -88.3 %
- Market cap
- USD 14.27M
- Enterprise value
- USD 5.73M
- P/E ratio (trailing)
- -0.56
- P/E ratio (forward)
- -0.76
- EPS (trailing)
- -3.36
- EPS (forward)
- -2.49
- PEG ratio
- 2.45
- Price to book
- 2.52
- Revenue growth
- -70.4 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 7.11
- Employees
- 28
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Cerenome, Inc. and compare it with other stocks.
Analyze CNSYAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Cerenome, Inc. shares.